Topotecan (topotecan): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Topotecan 1 mg/ml concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of:

Patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

Patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first- line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan 1mg/ml concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of

• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan 4 mg Powder for Concentrate for Solution for Infusion

Topotecan monotherapy is indicated for the treatment of:

patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first- line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan Actavis 1 mg powder for concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan Actavis 4 mg powder for concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of:

• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy

• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.


Route of administration: Injectable
Molecule: topotecan

Patients' opinions on Topotecan

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

Lung cancer

See the fact sheet